Pembrolizumab and bendamustine for Hodgkin lymphoma
Treatments studied
Part of Cancer clinical trials.
This study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy bendamustine can help people with Hodgkin lymphoma whose cancer returned or did not respond to earlier treatment. The goal is to see if this two-drug combination works better than either drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Hodgkin lymphoma that has come back or not responded to previous treatment.
- You have had at least one standard chemotherapy (like ABVD or BEACOPP).
- You cannot have, have declined, or are not eligible for a stem cell transplant using your own cells.
- You have not received bendamustine before.
- You are in generally good health (able to care for yourself) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (anti-PD-1 antibody) and radiation therapy for people with newly diagnosed, early-stage classic Hodgkin lymphoma that does not have certain risk factors. The goal is to see if this approach works well and has fewer side effects.
This Phase 2 study tests whether pembrolizumab combined with salvage (second-line) chemotherapy can treat people whose classical Hodgkin lymphoma has either come back after initial treatment or did not respond to initial treatment. You may benefit if you have first-relapsed or refractory classical Hodgkin lymphoma and meet other study rules.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This trial tests a combination of three drugs (chidamide, decitabine, and an immunotherapy) for people with classical Hodgkin lymphoma that has come back or not responded to at least two prior treatments. It is for patients who cannot or choose not to have a stem cell transplant.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard BEAM chemotherapy before a stem cell transplant can help people with relapsed Hodgkin lymphoma. It's for patients who are eligible for a transplant and have stable organ function.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.